Aptiv PLC (APTV) Expected to Post Quarterly Sales of $3.37 Billion

Wall Street analysts expect Aptiv PLC (NYSE:APTV) to post sales of $3.37 billion for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Aptiv’s earnings, with the lowest sales estimate coming in at $3.28 billion and the highest estimate coming in at $3.45 billion. Aptiv reported sales of $4.29 billion during the same quarter last year, which indicates a negative year over year growth rate of 21.4%. The firm is scheduled to announce its next earnings results on Wednesday, May 2nd.

On average, analysts expect that Aptiv will report full year sales of $3.37 billion for the current year, with estimates ranging from $13.58 billion to $14.10 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $14.70 billion per share, with estimates ranging from $14.34 billion to $15.08 billion. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Aptiv.

How to Become a New Pot Stock Millionaire

Aptiv (NYSE:APTV) last released its quarterly earnings data on Thursday, February 1st. The auto parts company reported $1.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.33 by ($0.05). Aptiv had a return on equity of 50.01% and a net margin of 8.27%. The business had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.31 billion. During the same period in the previous year, the company earned $1.83 EPS. Aptiv’s revenue was up 7.7% on a year-over-year basis.

Several equities research analysts have recently issued reports on the stock. BMO Capital Markets dropped their price objective on shares of Aptiv to $96.00 and set an “outperform” rating for the company in a research report on Tuesday, January 2nd. They noted that the move was a valuation call. Zacks Investment Research raised shares of Aptiv from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 6th. Piper Jaffray set a $105.00 price objective on shares of Aptiv and gave the stock a “buy” rating in a research report on Friday, December 8th. Longbow Research assumed coverage on shares of Aptiv in a research report on Friday, January 5th. They issued a “buy” rating and a $105.00 price objective for the company. Finally, Berenberg Bank raised shares of Aptiv from a “hold” rating to a “buy” rating in a research report on Wednesday. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $98.86.

In related news, SVP David Paja sold 6,287 shares of the firm’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $92.08, for a total transaction of $578,906.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Frank J. Dellaquila acquired 500 shares of Aptiv stock in a transaction on Friday, February 9th. The shares were bought at an average price of $86.50 per share, for a total transaction of $43,250.00. The disclosure for this purchase can be found here. 0.32% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Cambridge Investment Research Advisors Inc. bought a new position in Aptiv during the 4th quarter valued at $2,049,000. Envestnet Asset Management Inc. bought a new position in Aptiv during the 4th quarter valued at $2,394,000. Dixon Hubard Feinour & Brown Inc. VA bought a new position in Aptiv during the 4th quarter valued at $263,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp bought a new position in Aptiv during the 4th quarter valued at $14,141,000. Finally, Intercontinental Wealth Advisors LLC bought a new position in shares of Aptiv in the 4th quarter worth about $267,000. Hedge funds and other institutional investors own 92.50% of the company’s stock.

Shares of Aptiv stock traded down $2.08 during trading hours on Friday, hitting $83.82. The company’s stock had a trading volume of 1,578,401 shares, compared to its average volume of 1,774,427. Aptiv has a 1-year low of $61.73 and a 1-year high of $96.91. The firm has a market capitalization of $22,389.03, a P/E ratio of 18.06, a PEG ratio of 1.22 and a beta of 1.49. The company has a quick ratio of 1.29, a current ratio of 1.59 and a debt-to-equity ratio of 1.17.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3336571/aptiv-plc-aptv-expected-to-post-quarterly-sales-of-3-37-billion.html.

About Aptiv

Aptiv PLC, formerly Delphi Automotive PLC, is a global technology company serving the automotive sector. The Company designs and manufactures vehicle components, and provides electrical and electronic and active safety technology solutions to the global automotive and commercial vehicle markets. The Company’s segments include Electrical/Electronic Architecture, and Electronics & Safety.

Get a free copy of the Zacks research report on Aptiv (APTV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptiv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptiv and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

CommunityOne Bancorp  Earns News Impact Score of 0.19
CommunityOne Bancorp Earns News Impact Score of 0.19
Zcash Price Hits $267.03
Zcash Price Hits $267.03
Somewhat Positive Press Coverage Somewhat Unlikely to Affect New York REIT  Share Price
Somewhat Positive Press Coverage Somewhat Unlikely to Affect New York REIT Share Price
WPP  vs. Telaria  Head-To-Head Survey
WPP vs. Telaria Head-To-Head Survey
Brokerages Set Spero Therapeutics  Price Target at $27.67
Brokerages Set Spero Therapeutics Price Target at $27.67
Critical Contrast: XO Group  versus FTD Companies
Critical Contrast: XO Group versus FTD Companies


© 2006-2018 Ticker Report. Google+.